AstraZeneca Drops 7% on $400B BMS Merger Report
AstraZeneca shares dropped around 7% after the Financial Times reported the company held merger talks with Bristol Myers Squibb over several months. A deal would be valued at roughly $400 billion, which would rank among the largest corporate mergers ever attempted.